Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
200 hedge funds and large institutions have $2.04B invested in Sage Therapeutics in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 60 reducing their positions, and 30 closing their positions.
259% more call options, than puts
Call options by funds: $23.4M | Put options by funds: $6.52M
24% more capital invested
Capital invested by funds: $1.65B → $2.04B (+$396M)
13% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 60
1.55% more ownership
Funds ownership: 86.31% → 87.86% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 209 → 200 (-9)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$26.9M |
| 2 |
BlackRock
New York
|
+$22.4M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$17.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$16.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$23.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.7M |
| 4 |
Morgan Stanley
New York
|
-$8.99M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$5.55M |
SAGE Hedge Fund Activity: Q3 2022 in Review
200 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2022, worth a combined $2.04B — up 24% from $1.65B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of SAGE and 23 opened new positions — a net loss of 7 holders — while 60 trimmed existing stakes and 68 added.
The largest buyer was Janus Henderson Group, adding an estimated $26.9M. The largest seller was Marshall Wace, cutting an estimated $23.7M.
- 200 institutional investors held Sage Therapeutics (SAGE) as of Q3 2022, down from 209 in Q2 2022.
- Funds reported $2.04B of Sage Therapeutics stock for Q3 2022, up 24% quarter-over-quarter.
- 23 funds opened new Sage Therapeutics positions in Q3 2022 and 30 closed out, a net change of -7 holders.
- The largest Sage Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $26.9M added.
- The largest Sage Therapeutics seller in Q3 2022 was Marshall Wace, an estimated $23.7M sold.
Based on aggregated 13F filings for Q3 2022.